Merck & Co Inc (NYSE:MRK) | Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes

[Business Wire] – Merck , known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture . . . → Read More: Merck & Co Inc (NYSE:MRK) | Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes Similar Articles: Lockheed Martin Corporation (NYSE:LMT) | Lockheed and AeroVironment sign agreement on drone development Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – FDA panel backs Bristol diabetes drug after prior rejection Company Update: Abbott Laboratories (NYSE:ABT) – Experience ″A Day in the Life″ of an Insulin-using Patient with Diabetes through Interactive Infographic